Creo Medical Group PLC
LSE:CREO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Can Fin Homes Ltd
NSE:CANFINHOME
|
IN |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its Industry Average (0), the stock would be worth GBX-0.08 (101% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -3.6 | GBX12.13 |
0%
|
| Industry Average | 0 | GBX-0.08 |
-101%
|
| Country Average | 0 | GBX-0.07 |
-101%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
GBX47.4m
|
/ |
Jul 2025
£-8.8m
|
= |
|
|
GBX47.4m
|
/ |
Dec 2025
£-13.8m
|
= |
|
|
GBX47.4m
|
/ |
Dec 2026
£-9.1m
|
= |
|
|
GBX47.4m
|
/ |
Dec 2027
£-4m
|
= |
|
|
GBX47.4m
|
/ |
Dec 2028
£8.4m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Creo Medical Group PLC
LSE:CREO
|
50m GBP | -3.6 | 3 | |
| US |
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
171.2B USD | 45.5 | 60 | |
| US |
|
Abbott Laboratories
NYSE:ABT
|
158.3B USD | 13.8 | 25.2 | |
| US |
|
Stryker Corp
NYSE:SYK
|
125.3B USD | 19.8 | 38.6 | |
| IE |
|
Medtronic PLC
NYSE:MDT
|
106.9B USD | 12.9 | 23.2 | |
| US |
|
Boston Scientific Corp
NYSE:BSX
|
92B USD | 18.9 | 31.8 | |
| DE |
|
Siemens Healthineers AG
XETRA:SHL
|
40B EUR | 10.7 | 18.9 | |
| US |
|
Edwards Lifesciences Corp
NYSE:EW
|
48.9B USD | 24.9 | 45.5 | |
| US |
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
45.1B USD | 30.1 | 42.6 | |
| US |
|
Becton Dickinson and Co
NYSE:BDX
|
43.3B USD | 9.8 | 24.7 | |
| US |
|
Resmed Inc
NYSE:RMD
|
32B USD | 15.1 | 21.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Creo Medical Group PLC
Glance View
Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.
